Joseph Oro, MD
Family Medicine · Watertown, SDNPI 1720133887
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $639 and has fallen 74.6% since, to $162 in 2025. Among family medicine clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $13.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$488
- Lilly USA, LLC$370
- Johnson & Johnson$236
- Amgen$232
- Grifols USA, LLC$198
- Pfizer$188
- plus $719 from 20 others
What the payments were for
- Food & beverage$2,431100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $488 |
| Lilly USA, LLC | 26 | $370 |
| Johnson & Johnson | 28 | $236 |
| Amgen | 16 | $232 |
| Grifols USA, LLC | 12 | $198 |
| Pfizer | 22 | $188 |
| Daiichi Sankyo Inc. | 8 | $113 |
| Boehringer Ingelheim | 6 | $82 |
| Astellas Pharma US Inc | 5 | $73 |
| Amarin Pharma, Inc. | 5 | $63 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Novartis | 3 | $41 |
| Genentech USA, Inc. | 3 | $38 |
| Eisai Inc. | 2 | $29 |
| Abbott | 2 | $28 |
| Novo Nordisk | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Merck | 1 | $16 |
| GSK | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| AstraZeneca | 1 | $13 |
| Medtronic | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $11 |
| Organon | 1 | $8 |
How this compares
$2,431 in reported general payments places this provider in the 90th percentile of 408 family medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 51 | $47,614 |
| MounjaroTirzepatide | 38 | $46,238 |
| JardianceEmpagliflozin | 41 | $39,424 |
| EliquisApixaban | 58 | $27,691 |
| JanuviaSitagliptin Phosphate | 21 | $18,632 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 22 | $17,957 |
| OzempicSemaglutide | 16 | $17,501 |
| FarxigaDapagliflozin Propanediol | 34 | $16,405 |
| LinzessLinaclotide | 18 | $14,690 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $13,430 |
| Repatha SureclickEvolocumab | 19 | $10,243 |
| MyrbetriqMirabegron | 23 | $9,605 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $9,339 |
| EntrestoSacubitril/Valsartan | 27 | $8,968 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $8,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $236 | $47,61451 claims |
| Lilly USA, LLCMounjaro | $370 | $46,23838 claims |
| Boehringer IngelheimJardiance | $82 | $39,42441 claims |
| MerckJanuvia, Janumet Xr | $16 | $36,58943 claims |
| PfizerEliquis | $188 | $27,69158 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $14 | $21,69738 claims |
| Novo NordiskOzempic | $26 | $17,50116 claims |
| AstraZenecaFarxiga | $13 | $16,40534 claims |
| AbbVieLinzess | $488 | $14,69018 claims |
| Astellas Pharma US IncMyrbetriq | $73 | $9,60523 claims |
| NovartisEntresto | $41 | $8,96827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 408 family medicine providers in South Dakota.
Other family medicine in Watertown
- Jonathan McAreaveyWatertown$5K
- Aaron ShivesWatertown$5K
- Sarah ReiffenbergerWatertown$4K
- Daniel ReiffenbergerWatertown$3K
- Jessica HornWatertown$3K
- Kyla Helm-SwansonRapid City$22K
- Andrew BurchettSioux Falls$13K
- Lornell HansenSioux Falls$11K
- Michael GerlachMitchell$9K
- Jeffry MeyerSioux Falls$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.